Integer (NYSE:ITGR – Get Free Report) updated its FY24 earnings guidance on Thursday. The company provided EPS guidance of $5.01-5.43 for the period, compared to the consensus EPS estimate of $5.31. The company issued revenue guidance of 1.74-1.77 billion, compared to the consensus revenue estimate of $1.76 billion. Integer also updated its FY 2024 guidance to 5.010-5.430 EPS.
Integer Stock Performance
Shares of ITGR stock traded down $1.56 during trading hours on Friday, reaching $109.59. 604,251 shares of the company’s stock were exchanged, compared to its average volume of 342,875. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.80 and a quick ratio of 1.71. The company’s 50 day moving average is $112.91 and its two-hundred day moving average is $99.57. The company has a market cap of $3.67 billion, a P/E ratio of 40.36, a price-to-earnings-growth ratio of 1.71 and a beta of 1.10. Integer has a 1 year low of $69.40 and a 1 year high of $123.99.
Integer (NYSE:ITGR – Get Free Report) last announced its quarterly earnings data on Thursday, April 25th. The medical equipment provider reported $1.14 earnings per share for the quarter, topping analysts’ consensus estimates of $1.12 by $0.02. The firm had revenue of $414.80 million for the quarter, compared to analyst estimates of $412.78 million. Integer had a return on equity of 10.80% and a net margin of 5.68%. Integer’s quarterly revenue was up 9.5% on a year-over-year basis. During the same quarter in the prior year, the company posted $0.87 earnings per share. Equities research analysts anticipate that Integer will post 5.31 EPS for the current fiscal year.
Analyst Ratings Changes
Read Our Latest Stock Analysis on Integer
About Integer
Integer Holdings Corporation operates as a medical device outsource manufacturer in the United States, Puerto Rico, Costa Rica, and internationally. It operates through two segments, Medical and Non-Medical. The company offers products for interventional cardiology, structural heart, heart failure, peripheral vascular, neurovascular, interventional oncology, electrophysiology, vascular access, infusion therapy, hemodialysis, non-vascular, urology, and gastroenterology procedures.
See Also
- Five stocks we like better than Integer
- 3 Fintech Stocks With Good 2021 Prospects
- 3 Stocks Leading the U.S. Agriculture Comeback
- Low PE Growth Stocks: Unlocking Investment Opportunities
- How to Use Put Debit Spreads to Profit From Falling Stocks
- What Are Dividends? Buy the Best Dividend Stocks
- Alphabet Changes the Narrative with Its First-Ever Dividend
Receive News & Ratings for Integer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Integer and related companies with MarketBeat.com's FREE daily email newsletter.